Physician profile
Mark D Dalise
NPI 1801859723
$2,466.04
in general payments reported to CMS, 2019-2025
13 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $36.18 · 2021: $277 · 2022: $184 · 2023: $511 · 2024: $457 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,787.43 | 2019-2025 | N/A, Spinemap, Stryker Nav3 |
| Depuy Synthes Sales INC. | $157.74 | 2019-2023 | Viper |
| Vb Spine LLC | $137.05 | 2025 | Prolift |
| Providence Medical Technology, INC. | $120.46 | 2023 | |
| Irras USA, INC. | $60.05 | 2021-2022 | |
| Si-Bone, INC. | $44.81 | 2021-2023 | |
| Zimmer Biomet Holdings, INC. | $39.00 | 2024 | Allogenix |
| Arbor Pharmaceuticals, INC. | $36.18 | 2020 | |
| Spinal Elements, INC. | $21.45 | 2024 | |
| Mimedx Group, INC. | $17.95 | 2024 | |
| Prosidyan, INC | $15.52 | 2021 | |
| Medtronic, INC. | $14.96 | 2022 | |
| Medtronic USA, INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dalise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.